A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus on non-small cell lung cancer.

IF 2.8 3区医学 Q2 RESPIRATORY SYSTEM

BMC Pulmonary Medicine Pub Date : 2025-10-21 DOI:10.1186/s12890-025-03944-y

Jing Lin, Wenchao Xu, Leiming Xia, Congshu Zhang, Lei Ge, Junfeng Gao, Jian Bao, Yang Xu, Xiang Sun, Hongxia Li, Yi Wang

引用次数: 0

查看原文本刊更多论文

CAR-NK92MI联合免疫治疗复发或难治性实体肿瘤的I期临床试验：重点是非小细胞肺癌。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Pulmonary Medicine RESPIRATORY SYSTEM-

CiteScore

4.40

自引率

3.20%

发文量

423

审稿时长

6-12 weeks

期刊介绍： BMC Pulmonary Medicine is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.